{"id":"W2794342932","doi":"10.1158/1538-7445.sabcs17-pd3-12","title":"Abstract PD3-12: <i>PIK3CA</i> alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Clinical endpoint; Placebo; Population; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004656129,0.0003013487,0.0005900761,0.0002770082,0.0002562691,0.00005994871,0.0002304318,0.0001093264,0.001103197],"category_scores_gemma":[0.00002580715,0.0001877113,0.00009992154,0.0008598555,0.001312154,0.0002486539,0.00005178067,0.0006788119,0.000002638671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003963266,"about_ca_system_score_gemma":0.001135358,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009566952,"about_ca_topic_score_gemma":0.009696918,"domain_scores_codex":[0.9972838,0.0001523547,0.000501354,0.0005783929,0.0008872804,0.0005968039],"domain_scores_gemma":[0.9980415,0.0002390654,0.0001977135,0.0005989011,0.0007208684,0.0002019369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5933965,0.002381044,0.09149704,0.0002500245,0.0009310954,0.0001135291,0.0111679,0.002112531,0.131567,0.0001168608,0.0003127469,0.1661536],"study_design_scores_gemma":[0.2425966,0.007292726,0.6149693,0.002191259,0.0001532864,0.00003105705,0.001100588,0.001103395,0.126846,0.000195611,0.002864166,0.0006560261],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922106,0.003248518,0.0001267663,0.001401779,0.0001544727,0.002038161,0.0005887647,0.00002330573,0.00020767],"genre_scores_gemma":[0.9961899,0.0007632466,0.0001150707,0.0003322523,0.0005826479,0.001331519,0.00001548855,0.00006019349,0.0006096904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5234722,"threshold_uncertainty_score":0.9998099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09401084786466163,"score_gpt":0.4463718082474957,"score_spread":0.3523609603828341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}